BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Apr 30, 2024
Distillery Therapeutics

Activating PIEZO1 for lymphatic dysfunction

BioCentury | Apr 30, 2024
Distillery Therapeutics

PIEZO1 activation for food intake regulation in obesity

BioCentury | May 10, 2023
Data Byte

Translational spotlight on Alzheimer's targets

Academic studies identify clusters of new Alzheimer’s targets that modulate tauopathy and microglia, plus mechanisms including ATP metabolism
BioCentury | Dec 7, 2022
Distillery Therapeutics

Activating PIEZO1 for Alzheimer's disease

BioCentury | Oct 29, 2021
Discovery & Translation

Omics-based target identification in UK Biobank and COVID-19 cohorts 

Plus: technologies from Harvard, Texas A&M, Disney lab and more
BioCentury | Mar 13, 2019
Distillery Therapeutics

Inhibiting PIEZO1 for nerve damage

BioCentury | Nov 30, 2018
Targets & Mechanisms

Adhesion targets emerge at ASH 2018

Emerging science on adhesion molecules, RNA-binding proteins and more at ASH 2018
BioCentury | May 9, 2018
Distillery Therapeutics

Gastrointestinal

BioCentury | Apr 3, 2018
Distillery Therapeutics

Infectious disease

BioCentury | Mar 23, 2018
Preclinical News

PIEZO1 confers resistance to malaria

Items per page:
1 - 10 of 14